PL3463308T3 - Preparaty poli(tlenku alkilenu)-asparaginazy oraz sposoby ich wytwarzania i zastosowania - Google Patents

Preparaty poli(tlenku alkilenu)-asparaginazy oraz sposoby ich wytwarzania i zastosowania

Info

Publication number
PL3463308T3
PL3463308T3 PL17831465T PL17831465T PL3463308T3 PL 3463308 T3 PL3463308 T3 PL 3463308T3 PL 17831465 T PL17831465 T PL 17831465T PL 17831465 T PL17831465 T PL 17831465T PL 3463308 T3 PL3463308 T3 PL 3463308T3
Authority
PL
Poland
Prior art keywords
asparaginase
formulations
making
methods
same
Prior art date
Application number
PL17831465T
Other languages
English (en)
Polish (pl)
Inventor
Gianfranco Fornasini
Nadejda SOUKHAREVA
Christopher Phillips
Original Assignee
Servier IP UK Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60992770&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3463308(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier IP UK Limited filed Critical Servier IP UK Limited
Publication of PL3463308T3 publication Critical patent/PL3463308T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • C12N9/82—Asparaginase (3.5.1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
    • C12Y305/01001—Asparaginase (3.5.1.1)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL17831465T 2016-06-01 2017-06-01 Preparaty poli(tlenku alkilenu)-asparaginazy oraz sposoby ich wytwarzania i zastosowania PL3463308T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662344249P 2016-06-01 2016-06-01
US201662344252P 2016-06-01 2016-06-01
US201662344256P 2016-06-01 2016-06-01
EP17831465.4A EP3463308B1 (en) 2016-06-01 2017-06-01 Formulations of polyalkylene oxide-asparaginase and methods of making and using the same
PCT/US2017/035461 WO2018017190A2 (en) 2016-06-01 2017-06-01 Formulations of polyalkylene oxide-asparaginase and methods of making and using the same

Publications (1)

Publication Number Publication Date
PL3463308T3 true PL3463308T3 (pl) 2022-03-14

Family

ID=60992770

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17831465T PL3463308T3 (pl) 2016-06-01 2017-06-01 Preparaty poli(tlenku alkilenu)-asparaginazy oraz sposoby ich wytwarzania i zastosowania

Country Status (32)

Country Link
US (3) US12343387B2 (enExample)
EP (2) EP4019007A1 (enExample)
JP (2) JP7109427B2 (enExample)
KR (3) KR20230162139A (enExample)
CN (1) CN109640961B (enExample)
AU (1) AU2017299374B2 (enExample)
BR (1) BR112018074823B1 (enExample)
CA (1) CA3026070A1 (enExample)
CL (1) CL2018003418A1 (enExample)
CO (1) CO2018013753A2 (enExample)
CY (1) CY1124980T1 (enExample)
DK (1) DK3463308T3 (enExample)
ES (1) ES2905874T3 (enExample)
HR (1) HRP20212027T1 (enExample)
HU (1) HUE057856T2 (enExample)
IL (2) IL312621A (enExample)
LT (1) LT3463308T (enExample)
MX (2) MX388814B (enExample)
MY (1) MY198474A (enExample)
NZ (1) NZ788906A (enExample)
PH (1) PH12018502540A1 (enExample)
PL (1) PL3463308T3 (enExample)
PT (1) PT3463308T (enExample)
RS (1) RS62979B1 (enExample)
RU (1) RU2758796C2 (enExample)
SA (1) SA518400557B1 (enExample)
SG (1) SG11201810685WA (enExample)
SI (1) SI3463308T1 (enExample)
SM (1) SMT202200049T1 (enExample)
UA (1) UA123020C2 (enExample)
WO (1) WO2018017190A2 (enExample)
ZA (2) ZA201807943B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201812972D0 (en) 2018-08-09 2018-09-26 Univ Oxford Innovation Ltd Cell-penetrating peptides
GB201812980D0 (en) 2018-08-09 2018-09-26 Univ Oxford Innovation Ltd Cell-penetrating peptides
WO2020089743A1 (en) 2018-11-02 2020-05-07 Cadila Healthcare Limited Pharmaceutical composition of pegylated l-asparaginase
CA3122200A1 (en) 2018-12-07 2020-06-11 Oxford University Innovation Limited Linkers
KR20210107014A (ko) * 2018-12-24 2021-08-31 젠노바 바이오파마슈티컬스 리미티드 페가스파가제의 동결건조 조성물
MX2023011693A (es) * 2021-04-06 2023-12-15 Jazz Pharmaceuticals Ireland Ltd Formulaciones de l-asparaginasa.
CN114392237B (zh) * 2021-12-28 2024-02-02 上海允英生物医药科技有限公司 一种冻干病毒制剂及其制备方法
CN119326875A (zh) * 2024-12-23 2025-01-21 中国人民解放军总医院第三医学中心 L-ASNase在制备治疗膀胱癌药物中的应用及试剂盒

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2433883C2 (de) * 1973-07-20 1986-03-27 Research Corp., New York, N.Y. Verwendung von physiologisch aktiven Polypeptiden
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
EP0083439B1 (de) * 1981-12-31 1989-07-26 ASTA Pharma AG 4-Sulfido-oxazaphosphorine und deren Verwendung bei der Krebsbekämpfung und zur Immunsuppression
JPS58183626A (ja) 1982-04-21 1983-10-26 Nippon Oil Co Ltd 白血病治療用ｌ−アスパラギナ−ゼ固定化剤
US4729957A (en) 1984-12-13 1988-03-08 The United States Of America As Represented By The Department Of Health And Human Services Process for manufacture of L-asparaginase from erwinia chrysanthemi
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
AU5526690A (en) * 1989-04-19 1990-11-29 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5324844A (en) 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
GB9017002D0 (en) 1990-08-02 1990-09-19 Health Lab Service Board Improved method for the purification of erwina l-asparaginase
US5618710A (en) * 1990-08-03 1997-04-08 Vertex Pharmaceuticals, Inc. Crosslinked enzyme crystals
TW197439B (enExample) 1991-04-04 1993-01-01 Ueno Pharmaceutics Applic Res Co Ltd
US5283253A (en) 1991-09-23 1994-02-01 Florida State University Furyl or thienyl carbonyl substituted taxanes and pharmaceutical compositions containing them
AU3140093A (en) 1991-11-22 1993-06-15 University Of Mississippi, The Synthesis and optical resolution of the taxol side chain and related compounds
US5200534A (en) 1992-03-13 1993-04-06 University Of Florida Process for the preparation of taxol and 10-deacetyltaxol
EP0642586A4 (en) 1992-05-21 1995-11-29 Penn State Res Found CULTURAL -i (TAXUS) FABRIC AS A SOURCE OF TAXOL, RELATED TAXANS AND OTHER NEW ANTI-TUMOR / ANTI-VIRAL SUBSTANCES (01/20/94).
US5274137A (en) 1992-06-23 1993-12-28 Nicolaou K C Intermediates for preparation of taxols
US5294637A (en) 1992-07-01 1994-03-15 Bristol-Myers Squibb Company Fluoro taxols
US5202448A (en) 1992-08-14 1993-04-13 Napro Biotherapeutics, Inc. Processes of converting taxanes into baccatin III
CA2100808A1 (en) 1992-10-01 1994-04-02 Vittorio Farina Deoxy paclitaxels
FR2696463B1 (fr) 1992-10-05 1994-11-25 Rhone Poulenc Rorer Sa Procédé d'obtention de la désacétyl-10 baccatine III.
FR2696462B1 (fr) 1992-10-05 1994-11-25 Rhone Poulenc Rorer Sa Procédé d'obtention de la désacétyl-10 baccatine III.
FR2696461B1 (fr) 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa Nouveaux dérivés d'analogues du taxol, leur préparation et les compositions qui les contiennent.
FR2696458B1 (fr) 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa Procédé de préparation de dérivés du taxane.
FR2696464B1 (fr) 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa Nouveau procédé d'estérification de la baccatine III et de la désacétyl-10 baccatine III.
US5279949A (en) 1992-12-07 1994-01-18 Board Of Trustees Operating Michigan State University Process for the isolation and purification of taxol and taxanes from Taxus spp
US6277828B1 (en) 1993-08-20 2001-08-21 Syntex (U.S.A.) Inc. Pharmaceutical formulations of nerve growth factor
US5824701A (en) 1993-10-20 1998-10-20 Enzon, Inc. Taxane-based prodrugs
US5415869A (en) 1993-11-12 1995-05-16 The Research Foundation Of State University Of New York Taxol formulation
US5599902A (en) 1994-11-10 1997-02-04 Arizona Board Of Regents Acting On Behalf Of Arizona State University Cancer inhibitory peptides
US6087151A (en) 1995-02-08 2000-07-11 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo DNA coding for mammalian L-asparaginase
AU704973B2 (en) 1995-04-21 1999-05-13 Teikoku Hormone Mfg. Co., Ltd. Novel peptide derivatives
MX9800684A (es) * 1995-07-27 1998-04-30 Genentech Inc Formulacion de proteinas liofilizadas isotonicas estables.
US6537547B1 (en) 1996-06-07 2003-03-25 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Polypeptides having L-asparaginase activity
US5821263A (en) 1996-08-26 1998-10-13 Bristol-Myers Squibb Company Sulfenamide taxane derivatives
AU739028B2 (en) 1996-09-27 2001-10-04 Bristol-Myers Squibb Company Hydrolyzable prodrugs for delivery of anticancer drugs to metastatic cells
AU4966597A (en) 1996-11-19 1998-06-10 Daiichi Pharmaceutical Co., Ltd. Taxol derivatives
US5977386A (en) 1996-12-24 1999-11-02 Bristol-Myers Squibb Company 6-thio-substituted paclitaxels
PL195642B1 (pl) 1997-04-28 2007-10-31 Lilly Co Eli Sposób przetwarzania wodnego roztworu aktywowanego białka C
ATE265226T1 (de) 1997-06-09 2004-05-15 Los Angeles Childrens Hospital Verwendung von wolinella succinogenes asparaginase zur behandlung von asparagin- abhängiger krankheiten
US6991788B1 (en) 1997-06-09 2006-01-31 Childrens Hospital Los Angeles Utilization of wolinella succinogenes asparaginase to treat diseases associated with asparagine dependence
AU3574097A (en) 1997-06-20 1999-01-04 Baker Norton Pharmaceuticals, Inc. Soluble prodrugs of paclitaxel
US7288665B1 (en) 1997-08-18 2007-10-30 Florida State University Process for selective derivatization of taxanes
US5854051A (en) 1997-09-15 1998-12-29 Heska Corporation Parasitic helminth asparaginase proteins, nucleic acid molecules, and uses thereof
JPH1192468A (ja) 1997-09-17 1999-04-06 Yakult Honsha Co Ltd 新規なタキサン誘導体
DE69729128T2 (de) 1997-10-08 2005-04-28 Bio Research Corporation Of Yokohama, Yokohama Taxoid-derivate und verfahren zu ihrer herstellung
US6180095B1 (en) 1997-12-17 2001-01-30 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
WO1999048535A1 (en) 1998-03-26 1999-09-30 Schering Corporation Formulations for protection of peg-interferon alpha conjugates
ES2435141T3 (es) 1999-02-22 2013-12-18 University Of Connecticut Nuevas formulaciones de factor VIII libres de albúmina
US6323315B1 (en) 1999-09-10 2001-11-27 Basf Aktiengesellschaft Dolastatin peptides
CA2475738A1 (en) 2002-03-08 2003-09-18 Eli Lilly And Company Activated protein c formulations
EP1391213A1 (en) 2002-08-21 2004-02-25 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
ATE485331T1 (de) 2003-01-06 2010-11-15 Nektar Therapeutics Thiolselektive wasserlösliche polymerderivate
NZ572519A (en) 2006-06-30 2011-06-30 Defiante Farmaceutica Sa Recombinant host for producing l-asparaginase ii
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
JP2010524447A (ja) 2007-04-20 2010-07-22 ディーエスエム アイピー アセッツ ビー．ブイ． アスパラギナーゼ酵素変異体およびその使用
FI20070455A0 (fi) 2007-06-08 2007-06-08 Reagena Ltd Oy Menetelmä syöpäsairauksien tai tulehdussairauksien hoitoon
WO2011003633A1 (en) 2009-07-06 2011-01-13 Alize Pharma Ii Pegylated l-asparaginase
NZ605873A (en) 2010-06-25 2015-02-27 Shire Human Genetic Therapies Methods and compositions for cns delivery of arylsulfatase a
WO2012028945A2 (en) 2010-09-01 2012-03-08 Indian Institute Of Technology, Dehli Mutants of l-asparagine
RU2441914C1 (ru) 2010-10-06 2012-02-10 Учреждение Российской академии медицинских наук Научно-исследовательский институт биомедицинской химии имени В.Н. Ореховича РАМН (ИБМХ РАМН) Способ получения субстанции рекомбинантной l-аспарагиназы erwinia carotovora
CN102138909B (zh) 2010-12-30 2013-03-13 常州千红生化制药股份有限公司 门冬酰胺酶冻干粉针剂及其制备方法以及门冬酰胺酶溶解液
WO2013055699A1 (en) 2011-10-10 2013-04-18 Children's Hospital Los Angeles Novel asparaginase and methods for treating diseases associated with asparagine dependence
CN102657852A (zh) * 2012-05-22 2012-09-12 范铭琦 重组沃氏菌天门冬酰胺酶药物组合物及其制备法和应用

Also Published As

Publication number Publication date
UA123020C2 (uk) 2021-02-03
RU2018146395A3 (enExample) 2020-07-09
JP7109427B2 (ja) 2022-07-29
ES2905874T3 (es) 2022-04-12
KR20230162139A (ko) 2023-11-28
KR20220165820A (ko) 2022-12-15
RU2758796C2 (ru) 2021-11-01
CA3026070A1 (en) 2018-01-25
RU2018146395A (ru) 2020-07-09
NZ749069A (en) 2025-02-28
CY1124980T1 (el) 2023-01-05
US12343387B2 (en) 2025-07-01
KR102473887B1 (ko) 2022-12-06
SA518400557B1 (ar) 2024-02-29
AU2017299374A1 (en) 2018-12-20
ZA202202259B (en) 2022-11-30
US20250242004A1 (en) 2025-07-31
DK3463308T3 (da) 2022-01-31
AU2017299374B2 (en) 2021-05-27
MX2021015544A (es) 2022-02-23
CL2018003418A1 (es) 2019-05-24
WO2018017190A2 (en) 2018-01-25
IL263349A (en) 2019-01-31
EP3463308A4 (en) 2019-12-18
SI3463308T1 (sl) 2022-04-29
LT3463308T (lt) 2022-02-10
BR112018074823A2 (pt) 2019-03-06
HUE057856T2 (hu) 2022-06-28
IL263349B1 (en) 2024-06-01
SG11201810685WA (en) 2018-12-28
WO2018017190A3 (en) 2018-03-01
MY198474A (en) 2023-08-31
IL263349B2 (en) 2024-10-01
SMT202200049T1 (it) 2022-03-21
EP4019007A1 (en) 2022-06-29
EP3463308B1 (en) 2021-12-01
NZ788906A (en) 2025-07-25
US20240108701A1 (en) 2024-04-04
KR102783452B1 (ko) 2025-03-19
CO2018013753A2 (es) 2019-01-18
PH12018502540A1 (en) 2019-04-08
KR20190015366A (ko) 2019-02-13
MX2018014916A (es) 2019-07-18
CN109640961B (zh) 2021-11-02
US20190240300A1 (en) 2019-08-08
HRP20212027T1 (hr) 2022-04-01
EP3463308A2 (en) 2019-04-10
IL312621A (en) 2024-07-01
JP2019521179A (ja) 2019-07-25
ZA201807943B (en) 2022-09-28
MX388814B (es) 2025-03-20
BR112018074823B1 (pt) 2024-02-27
CN109640961A (zh) 2019-04-16
JP2022071060A (ja) 2022-05-13
PT3463308T (pt) 2022-03-11
RS62979B1 (sr) 2022-03-31

Similar Documents

Publication Publication Date Title
ZA201805805B (en) Formulations and methods
IL263828A (en) Triglyceride ear preparations and their uses
ZA202202259B (en) Formulations of polyalkylene oxide-asparaginase and methods of making and using the same
IL255801A (en) Liposomal nanoconstructs and methods of making and using the same
IL256621A (en) Carrier-binder preparations and methods for their preparation and use
ZA201701244B (en) Carrier-antibody compositions and methods of making and using the same
EP3129024A4 (en) Nicotine formulations and methods of making the same
ZA202104969B (en) Compositions comprising 15-hepe and methods of using the same
IL265870A (en) Nanoparticle formulations and methods of making and using thereof
GB201519128D0 (en) Solid forms and methods of preparing the same
EP3310354A4 (en) Improved formulations of deferasirox and methods of making the same
IL285928A (en) Fulvestrant formulations and methods of using them
IL266132B (en) Pharmaceutical formulations and methods for their preparation
IL258139A (en) Nicotine compositions and methods for their preparation and use
ZA201903928B (en) Compositions comprising methylphenidate-prodrugs, processes of making and using the same
GB201715820D0 (en) Compositions and methods
GB201705626D0 (en) Compositions and methods
ZA201807665B (en) Methods and compositions
IL261794A (en) Preparations and methods for using them
GB201818904D0 (en) New formulations and methods
ZA201807782B (en) Methods and compositions
GB201716745D0 (en) New formulations and uses thereof
GB201621959D0 (en) Compositions and their use
AU2016900251A0 (en) Bioherbicidal formulations and methods
GB201602665D0 (en) Compositions and their use